FDA Approves First Stent for Brain Pressure Disorder

In a significant development for patients with severe idiopathic intracranial hypertension (IIH), the US Food and Drug Administration (FDA) has approved Serenity Medical's River stent. This marks the first time the agency has granted approval for a cerebral venous stent specifically indicated for this condition. The River stent is designated for adult IIH patients who have significant stenosis and have not responded to medical treatments. It functions by holding open narrowed brain veins to enhance blood drainage, thereby reducing cranial pressure and alleviating debilitating symptoms like severe headaches and vision loss.

The FDA's decision was based on findings from the 39-subject River study. This trial met its primary safety endpoint, reporting a major adverse event rate of 5.4% at one year. Participants also experienced notable improvements in cerebrospinal fluid pressure, reduced headaches, and better visual function. The study's results, published in the Journal of Neurointerventional Surgery, indicate that the River stent offers a crucial new therapeutic option for individuals with severe IIH who have exhausted conventional treatment avenues.